These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 19619171)

  • 1. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients.
    Wahrmann M; Bartel G; Exner M; Regele H; Körmöczi GF; Fischer GF; Böhmig GA
    Transpl Int; 2009 Oct; 22(10):982-9. PubMed ID: 19619171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens.
    Bartel G; Wahrmann M; Exner M; Regele H; Schillinger M; Hörl WH; Böhmig GA
    Transplantation; 2007 Mar; 83(6):727-33. PubMed ID: 17414705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients.
    Bartel G; Wahrmann M; Schwaiger E; Kikić Ž; Winzer C; Hörl WH; Mühlbacher F; Hoke M; Zlabinger GJ; Regele H; Böhmig GA
    Transpl Int; 2013 Feb; 26(2):121-30. PubMed ID: 23145861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of complement-fixing antibodies in cardiac transplantation.
    Rose ML; Smith JD
    Hum Immunol; 2009 Aug; 70(8):605-9. PubMed ID: 19375471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection.
    Hönger G; Wahrmann M; Amico P; Hopfer H; Böhmig GA; Schaub S
    Transplantation; 2010 Jun; 89(12):1471-5. PubMed ID: 20395886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance and implications of capillaritis during acute rejection of kidney allografts.
    Cosio FG; Lager DJ; Lorenz EC; Amer H; Gloor JM; Stegall MD
    Transplantation; 2010 May; 89(9):1088-94. PubMed ID: 20216485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Cardarelli F; Pascual M; Tolkoff-Rubin N; Delmonico FL; Wong W; Schoenfeld DA; Zhang H; Cosimi AB; Saidman SL
    Transpl Int; 2005 May; 18(5):532-40. PubMed ID: 15819801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients.
    Wahrmann M; Exner M; Schillinger M; Haidbauer B; Regele H; Körmöczi GF; Hörl WH; Böhmig GA
    Am J Transplant; 2006 May; 6(5 Pt 1):1033-41. PubMed ID: 16611341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?
    Cicciarelli JC; Lemp NA; Chang Y; Koss M; Hacke K; Kasahara N; Burns KM; Min DI; Naraghi R; Shah T
    J Immunol Res; 2017; 2017():1652931. PubMed ID: 28182088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.
    Gaston RS; Cecka JM; Kasiske BL; Fieberg AM; Leduc R; Cosio FC; Gourishankar S; Grande J; Halloran P; Hunsicker L; Mannon R; Rush D; Matas AJ
    Transplantation; 2010 Jul; 90(1):68-74. PubMed ID: 20463643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of preformed donor-specific antibodies and C4d on early liver allograft function.
    Perera MT; Silva MA; Murphy N; Briggs D; Mirza DF; Neil DA
    Scand J Gastroenterol; 2013 Dec; 48(12):1444-51. PubMed ID: 24131305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
    Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
    Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.
    Seveso M; Bosio E; Ancona E; Cozzi E
    Contrib Nephrol; 2009; 162():87-98. PubMed ID: 19001816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C4d binding correlated with strong HLA antibodies involved in graft failures.
    Mizutani K; Gotoh M
    Transplant Proc; 2010 Dec; 42(10):4021-5. PubMed ID: 21168616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
    Aubert V; Venetz JP; Pantaleo G; Pascual M
    Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.